Flexion Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, FLXN, Flexion Therapeutics Inc, priceseries

Flexion Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
16.27
Close
16.50
High
16.76
Low
16.27
Previous Close
16.44
Daily Price Gain
0.06
YTD High
17.82
YTD High Date
Nov 4, 2019
YTD Low
8.76
YTD Low Date
Aug 5, 2019
YTD Price Change
4.04
YTD Gain
32.42%
52 Week High
17.82
52 Week High Date
Nov 4, 2019
52 Week Low
8.76
52 Week Low Date
Aug 5, 2019
52 Week Price Change
0.51
52 Week Gain
3.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
17.79
Jul 31. 2017
23.29
29 Trading Days
30.91%
Link
LONG
Aug 22. 2017
22.89
Sep 1. 2017
24.26
8 Trading Days
5.97%
Link
LONG
May 9. 2019
11.55
May 28. 2019
12.53
12 Trading Days
8.46%
Link
LONG
Aug 23. 2019
11.07
Sep 26. 2019
14.39
23 Trading Days
29.96%
Link
LONG
Oct 23. 2019
15.19
Nov 8. 2019
16.24
12 Trading Days
6.89%
Link
Company Information
Stock Symbol
FLXN
Exchange
NasdaqGM
Company URL
http://www.flexiontherapeutics.com
Company Phone
(781) 305-7777
CEO
Michael D. Clayman
Headquarters
Massachusetts
Business Address
10 MALL ROAD, SUITE 301, BURLINGTON, MA 01803
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001419600
About

Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies. It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis. Its products include Zilretta. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Description

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading